BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

iRhythm Technologies Inc. Announces Publication of Zio® Patch Study Demonstrating Superior Ability to Detect Atrial Fibrillation


3/7/2013 9:57:04 AM

SAN FRANCISCO, CA--(Marketwire - March 07, 2013) - iRhythm Technologies, Inc., a medical device, service and technology company that develops and markets simple, innovative diagnostic monitoring solutions, today announced clinical study findings showing that use of the Zio® Patch resulted in a change in treatment strategy for nearly one-third of patients with paroxysmal atrial fibrillation (AF). The data, which will be published in Pacing and Clinical Electrophysiology (PACE) Journal on March 12, showed that the Zio Patch ambulatory cardiac monitoring system demonstrated improved clinical accuracy and detection of potentially malignant arrhythmias in AF patients compared with a 24-hour Holter Monitor in the same patients.

The self-controlled study, conducted by Dr. Michael A. Rosenberg, Dr. Peter J. Zimetbaum and colleagues at Beth Israel Deaconess Medical Center's Division of Electrophysiology in Boston, compared iRhythm's Zio Patch to a 24-hour Holter monitor in 74 patients with AF who were referred for monitoring to detect and characterize their arrhythmias.

"The findings from this peer-reviewed research further validate the clinical and patient benefits of the Zio Patch and support its progression toward becoming a new standard of care for ambulatory cardiac rhythm diagnostics," said Kevin King, iRhythm's president and chief executive officer. "iRhythm is committed to providing high-yield diagnostic data via a very simple solution for clinicians and their cardiac patients who have not benefited from significant innovation in the field of ambulatory cardiac monitoring in many years."

"The results of this peer-reviewed study corroborate what we consistently see in everyday practice, which is that the combination of improved patient compliance and longer-term monitoring can enable physicians to better detect episodes of paroxysmal atrial fibrillation and make more informed treatment decisions based upon this clinical information," said Judy Lenane, chief clinical officer for iRhythm. "Patients have consistently expressed appreciation for the low-profile, wire-free form factor of the Zio Patch, which enables them to shower and go about their daily activities without the bulk and discomfort of a traditional Holter."

Study Results
Overall, the study results showed that the Zio Patch was superior to a 24-hour monitor in detecting AF episodes and comparable in quantifying AF burden. Specifically, the Zio Patch identified AF episodes in 35 percent of patients who were found to have no AF by the Holter monitor. The Zio Patch also provided the additional benefit of detecting other more malignant arrhythmias due to the longer duration of detection. These benefits led to clinically meaningful changes in the existing treatment plans for 21 of the study patients (28.4 percent of study participants).

The Zio Patch was well tolerated by a majority of the study participants, with a mean wear time of 10.8 days (range of 4-14 days overall).

The study concluded that the promising data from this pilot study suggests that the Zio Patch device may represent a more convenient and efficient method of outpatient arrhythmia detection than current methods using Holter monitors, event recorders, or mobile cardiac outpatient telemetry.

About the Zio Patch System
The Zio Patch System is comprised of the Zio Patch and Zio Report, which work together to enable cost-effective care while providing a positive patient experience. The Zio Patch is a single-use, noninvasive waterproof continuous recording ambulatory cardiac rhythm monitor that optimizes and simplifies arrhythmia diagnosis. Cleared by the FDA for up to 14 days of continuous monitoring, the Zio Patch has monitored over 100,000 patients since its commercial introduction in 2011.

About iRhythm Technologies, Inc.
iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. For more information, please visit www.irhythmtech.com.


Media Contacts
Jenna Green
iRhythm Technologies
Email Contact
650.400.4273

Jessica Volchok
WCG for iRhythm Technologies
Email Contact
310.774.3423



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES